Pharmaceutical R&D Improves with Artificial Intelligence (AI)

The use of AI and robotics is helping to speed the discovery and development of new pharmaceutical materials and chemicals, as well as repurpose existing drugs. AI and machine learning have been vital to the development of Coronavirus vaccines and in tracking the spread of the virus. AI’s ability to analyze staggering amounts of data and conduct simulations around the clock exponentially sped the creation of vaccines and virus therapies. The virus has proven to many researchers that AI is a valuable tool for identifying signals to point the way towards successful treatments.

Massachusetts based startup Kebotix (www.kebotix.com), for example, uses a combination of AI and robotics to speed the development process and reduce costs. Deep Genomics (www.deepgenomics.com), another startup, uses AI to search for oligonucleotide molecules to treatments of genetic diseases such as neurodegenerative and metabolic disorders. Yet another new company, Atomwise (www.atomwise.com), uses neural networks to analyze big data for its drug discovery process.

Meanwhile, Pharnext (www.pharnext.com) puts AI to work to find ways to leverage existing drugs into better treatments, alone or in combination. The process analyzes millions of cases drug and patient data to isolate significant patterns. In late 2018, Pharnext reported positive results for patients suffering from a neurodegenerative disorder called Charcot-Marie-Tooth disease (CMT) when treated with a novel compound called PXT3003. The therapy was in Phase 3 trials as of early 2023. The firm is also working on drugs for treating Alzheimer’s and ALS.

In late 2021, New York startup Paige.AI, Inc. received FDA approval for its Paige Prostate diagnosis tool for prostate cancer. The tool utilizes neural network technology (in which layers of artificial neurons function in a human brain-like manner in order to best analyze data). Paige’s technology recognizes patterns typically found in prostate biopsy slides. Paige Prostate is one of about 300 AI-based medical systems marketed in the U.S. Other AI-enabled drug companies include Helixon Ltd. and Ainnocence.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Become a Plunkett Research Online subscriber to gain unlimited access to our massive amount of vital industry data and market research.

✔ 100,000 Industry Statistics
✔ 500 Industries Analyzed for Market Size, Profits and Forecasts
✔ 150,000 Industry Executives Profiled
✔ 25,000 Companies Profiled, Ranked and Analyzed
✔ 1,000 Vital Trends Analyzed, totaling 1,000,000 words

Learn More

Pharmaceutical R&D Improves with Artificial Intelligence (AI), Business and Industry Trends Analysis

A Representative List of Organizations that Have Used our Research and Products:

How to access Plunkett Research data.

What data challenge can we help you solve today?

Take a Tour

Contact

Testimonials